Coppell Advisory Solutions LLC Buys 280 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Coppell Advisory Solutions LLC raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 137.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 484 shares of the pharmaceutical company’s stock after buying an additional 280 shares during the quarter. Coppell Advisory Solutions LLC’s holdings in Vertex Pharmaceuticals were worth $193,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. MGO One Seven LLC raised its position in shares of Vertex Pharmaceuticals by 68.6% in the 4th quarter. MGO One Seven LLC now owns 5,742 shares of the pharmaceutical company’s stock worth $2,312,000 after purchasing an additional 2,336 shares during the last quarter. Dark Forest Capital Management LP lifted its stake in shares of Vertex Pharmaceuticals by 54.6% in the fourth quarter. Dark Forest Capital Management LP now owns 1,657 shares of the pharmaceutical company’s stock worth $667,000 after buying an additional 585 shares in the last quarter. Alta Advisers Ltd grew its holdings in shares of Vertex Pharmaceuticals by 24.4% during the fourth quarter. Alta Advisers Ltd now owns 871 shares of the pharmaceutical company’s stock valued at $351,000 after buying an additional 171 shares during the last quarter. Fayez Sarofim & Co bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $4,185,000. Finally, Stifel Financial Corp raised its holdings in Vertex Pharmaceuticals by 32.3% in the 4th quarter. Stifel Financial Corp now owns 124,844 shares of the pharmaceutical company’s stock worth $50,275,000 after acquiring an additional 30,512 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $535.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday. Wells Fargo & Company downgraded Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price objective for the company. in a report on Thursday, January 30th. Truist Financial upped their target price on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and lifted their price target for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Finally, Royal Bank of Canada increased their price objective on shares of Vertex Pharmaceuticals from $408.00 to $420.00 and gave the company a “sector perform” rating in a research report on Tuesday, April 1st. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $514.91.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP David Altshuler sold 3,231 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now owns 26,512 shares of the company’s stock, valued at $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the completion of the transaction, the executive vice president now directly owns 64,021 shares of the company’s stock, valued at $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,315 shares of company stock valued at $2,121,012. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Stock Up 0.0 %

NASDAQ VRTX opened at $492.47 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The stock’s 50 day moving average is $489.14 and its 200 day moving average is $466.12. The stock has a market cap of $126.46 billion, a PE ratio of -223.85, a P/E/G ratio of 2.11 and a beta of 0.50.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.